Vertex Pharmaceuticals Inc. is moving forward as fast as it can with the development of next-generation correctors as part of triple-drug combination therapies that may expand treatment to new cystic fibrosis patients, according to newly revealed efficacy in early clinical trials. The company plans to rapidly complete Phase II trials and start one or two pivotal studies in 2018.
Vertex will move from Phase I and II studies into a Phase III program in less than a year now...